Category: Alzheimer Diagnosis News

Neurologists discuss the major milestones in identifying biomarkers for detecting early Alzheimer’s disease over the past two decades.

Globalization of ADRD clinical trials has become a pressing need as 68% of the people living with ADRD will reside in low-middle-income countries (LMICs) by 2025.

For 20 years, the Knight Alzheimer Disease Research Center has worked to boost diversity in clinical trials.

A new diagnostic tool by C2N Diagnostics is an important new tool for physicians in the evaluation of Alzheimer disease. It could pave the way for earlier diagnosis and treatment and greater enrollment in clinical trials.

Scientists are launching a study designed to make or break the hypothesis that Alzheimer’s is caused by a sticky substance called beta-amyloid. The study will give an experimental anti-amyloid drug to people as young as 18 who have gene mutations that often cause Alzheimer’s to appear in their 30s or 40s.

A five-year, $9 million grant from the National Institute on Aging of the National Institutes of Health (NIH) will fund research led by several investigators at Washington University School of Medicine in St. Louis and at the University of Texas at San Antonio to answer that question.

The Alzheimer’s disease (AD) drug lecanemab’s recent success in Biogen’s Phase III clinical trials might have more to do with its effect in increasing levels of soluble amyloid-beta than in decreasing amyloid plaques in the brain, the findings of a new study published in the Journal of Alzheimer’s Disease on October 4, 2022, suggests.

Carlos Cruchaga, PhD, the Barbara Burton and Reuben M. Morriss III Professor in psychiatry, is one of three Zenith Fellows selected this year and one of only 146 Alzheimer’s researchers chosen for the honor since it was created in 1991.

Dr. Jorge Llibre is a Washington University neurologist that researches Alzheimer’s. He says research shows the Hispanic community is two times more likely to develop Alzheimer’s or dementia than non-Hispanics.

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia?

Could drugs prevent Alzheimer’s? These trials aim to find out